4DMedical Shares Drop 55% On Month After Breakneck Rally: Why The Shift in Sentiment?

4DMedical shares (4DX) extended their dramatic reversal from recent highs on Thursday, closing down 10.53% at A$3.40 as markets reassess the medical imaging company’s valuation despite a string of high-profile contract wins that fuelled a spectacular 1,000% rally over the past year.

The 4DMedical share price has now come down 55% from its April high of A$7.55, wiping out more than A$2B in market cap. Such has been the reversal, that shares are now down 25% year-to-date, despite remaining up approximately 1,000% over the trailing twelve months, a dramatic illustration of both the company’s meteoric rise and its equally swift correction. The latest double-digit decline adds to mounting pressure on a stock that has become one of the ASX’s most volatile healthcare names.

Driving the 4DX Share Price

4DMedical’s recent newsflow has been positive on a fundamental level, making the share price collapse all the more striking. In mid-April, the company announced a one-year contract with pharmaceutical giant GlaxoSmithKline to supply its quantitative lung-imaging analytics for pulmonary drug development and clinical research, effective 1 May 2026. Around the same time, 4DMedical secured inclusion in the S&P/ASX 200 index, effective 20 April, following its earlier addition to the ASX 300 in early March.

The GSK deal was widely interpreted as validation by a top-tier global pharmaceutical company that 4DMedical’s CT:VQ technology, which provides functional lung imaging, has genuine value in drug development pipelines. The ASX 200 inclusion forced a range of index and benchmarked funds to acquire the stock, contributing to incremental demand that helped push shares toward the A$7 level.

Earlier in the year, 4DMedical expanded a distribution agreement with Philips to cover the United States and Canada, with Philips committing to a minimum order of approximately US$10 million (roughly A$15 million) across 2026-27. In late March, the company signed a contract with Mayo Clinic, one of the world’s most prestigious medical centres, triggering a one-day surge of around 30% at the time.

Yet behind these commercial milestones lies a more complex capital markets story.

4DMedical completed at least two large institutional placements in 2026, raising a combined A$150 million in January and additional capital in March. Total placements for the year reached approximately A$233 million, leaving the company with pro-forma cash of around A$283 million at 31 March. The January raise included an institutional offering of about A$79 million at A$3.80 per share, with a subsequent placement later in the first quarter at A$5.90.

While these raises removed near-term funding risk and provided a war chest for aggressive US and global expansion, they have also created a significant supply overhang. With the share price now trading below both major placement prices, investors who participated are sitting on meaningful losses, creating natural selling pressure as some funds cut positions or de-risk.

What Next?

If 4DMedical can demonstrate rapid revenue growth and scalability, then the bull case for a high-margin medical technology platform could potentially look to once again take the fore. Yet if growth appears slower or more modest than the hype suggested, the pullback could continue as markets abandon the “hype multiples” that characterised the stock’s run to A$7. The heavy dilution from this year’s placements means the company must now deliver materially stronger financial performance simply to justify current levels, let alone a return to recent highs.

The next major test will come with upcoming financial results that can demonstrate whether the Mayo Clinic, GSK, and Philips relationships are translating into meaningful revenue. Until then, 4DMedical appears likely to remain one of the ASX’s most volatile healthcare stocks that may be too much to take for many.